Proactive Investors
28 Sept 2026, 07:04 UTC · 2h ago
Verdict
Headline takes no side. We score POLB +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
Poolbeg Pharma has dosed eight patients in its TOPICAL trial testing POLB 001 for the prevention of cytokine release syndrome.
Newpublished 28 Sep 2026
So whatWith 8 of 30 target patients dosed, the company has reached ~27% of its recruitment goal.
More positive than 79% of claims this week
An interim review of a six-patient safety group recommended that the TOPICAL trial continue unchanged.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Newpublished 28 Sep 2026
So whatPassing the initial safety hurdle reduces the risk of immediate trial termination before the full 30-patient cohort is reached.
More positive than 66% of claims this week
Poolbeg Pharma raised £3.5 million in July to fund the TOPICAL trial and an oral weight-loss drug study through to completion.
Priced inraised in July
So whatThis funding provides a runway that covers both current clinical pipelines, reducing the likelihood of a capital raise in Q4 2026.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company reported positive progress in its TOPICAL trial, including successful dosing and a positive interim safety review.
Near neutral — 92% of ticker scores this week are stronger
The company is mentioned only as the manufacturer of a drug being used in another company's clinical trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
7h ago
—
No price for POLB right now — the quote feed didn't answer.
POLB chart →
